A
Alcista
Alcista · 25%ONCO
$4.05
Precio del escenario
$0.598
+0.155 (+25.98%)Al cierre
Loading chart…
- Máximo
- 0.678
- Apertura
- 0.508
- Precio medio ponderado por volumen
- 0.59
- Volumen
- 45.22M
- Capitalización
- —
- Mínimo
- 0.481
- Importe
- 26.48M
- EV/EBITDA, TTM
- 0.00
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test.
Análisis de IA of Onconetix Inc (ONCO)
VenderOnconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.
Métricas de valoración
El PER previsto actual de Onconetix Inc (ONCO) es 0.00, frente a su media de 5 años de -2.37.
Escenarios de precio de Alphio AI para ONCO
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Cronología de eventos
Noticias
8.510-26NewsfilterOnconetix Approves 1-for-10 Reverse Stock Split
8.509-15NASDAQ.COMOnconetix Provides Strategic Financing to Realbotix Ahead of Acquisition
8.509-03NASDAQ.COMOnconetix Acquires Realbotix, Launches Robot Pilot Program
9.508-27Yahoo FinanceOncopeptides Reports Strong Q2 2026 Earnings Growth
8.508-06GlobenewswireOnconetix Advances Acquisition of Realbotix Amid Humanoid Robotics Adoption
Preguntas frecuentes sobre ONCO, respondidas por Alphio AI
Onconetix, Inc. is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men’s health and oncology. The Company owns Proclarix, an in vitro diagnostic test for prostate cancer approved for sale in the European Union under the In Vitro Diagnostic Regulation. Proclarix is an easy-to-use next generation protein-based blood test that can be done with the same sample as a patient’s regular Prostate-Specific Antigen (PSA) test. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Onconetix Inc is not a good buy right now due to its current price of $0.42, which is down 99.48% year-to-date, and an RSI of 26.369 indicating it is oversold. The company has reported a gross margin of only 25.13% in Q2 2026, which is significantly lower than previous quarters, and a negative net income of -$2,867,303 in the same quarter. The main risk is the substantial 5-day change of -12.70%, reflecting ongoing volatility and lack of investor confidence.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.